Estrella Immunopharma (ESLA) Cash & Current Investments (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Cash & Current Investments of $1.9 million for Q1 2026, up 357.3% year-over-year from $421473.0 in Q1 2025, and up 39.23% quarter-over-quarter from $1.4 million in Q4 2025.
Estrella Immunopharma (ESLA) Cash & Current Investments (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Cash & Current Investments for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 357.3% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 357.3% YoY), while the FY2025 annual figure was $1.4 million, up 50.97% from the prior year.
- Cash & Current Investments improved to $1.9 million in Q1 2026 per ESLA's latest filing, from $1.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $22.1 million in Q3 2023 and bottomed at $29390.0 in Q1 2023.
- Historically, Cash & Current Investments has averaged $3.1 million across 5 years, with a median of $1.4 million in 2025.
- Annual changes were most pronounced in 2023 — Cash & Current Investments surged 29916.81% — and 2024, when it slumped 91.87%.
- Estrella Immunopharma's Cash & Current Investments stood at $40802.0 in 2022, then soared by 22070.52% to $9.0 million in 2023, then tumbled by 89.86% to $916916.0 in 2024, then soared by 50.97% to $1.4 million in 2025, then soared by 39.23% to $1.9 million in 2026.
- Business Quant data shows ESLA's Cash & Current Investments at $1.9 million in Q1 2026, $1.4 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 146,670.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146,670.00 |
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 421,473.00 |
| Dec 31, 2024 | 916,916.00 |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.70 Mn |
| Dec 31, 2023 | 9.05 Mn |
| Sep 30, 2023 | 22.14 Mn |
| Jun 30, 2023 | 2.48 Mn |
| Mar 31, 2023 | 29,390.00 |
| Dec 31, 2022 | 40,802.00 |
| Sep 30, 2022 | 73,752.00 |
| Jun 30, 2022 | 88,281.00 |
| Mar 31, 2022 | 321,724.00 |
| Dec 31, 2021 | 478,868.00 |
| Sep 30, 2021 | 321,724.00 |